Clinical trials
Alzheimer's Disease Dementia clinical trials
Below are recruiting alzheimer's disease dementia clinical trials, each written for real people, not researchers. We’re tracking 461 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT00950430Enrolling by invitationPhase 4
Brain scan study for amyloid plaques in adults
This study uses brain imaging to look for amyloid plaques (abnormal protein deposits) as people age. It may help researchers better understand how these changes develop over time.
Rochester, MinnesotaAges 30–100 - NCT07571161RecruitingPhase 3
Donanemab for early Alzheimer's disease in Chinese participants
This trial tests a drug called donanemab in people who have early signs of Alzheimer's disease (amyloid buildup in the brain) but are still thinking clearly. The goal is to see if the drug can slow or prevent cognitive decline before memory problems start.
BeijingAges 55–80 - NCT07543094Enrolling by invitation
Brain Stimulation for Early Alzheimer's Memory and Thinking
This study tests whether a special type of brain stimulation called temporal interference stimulation can improve memory and thinking skills in people with early-stage Alzheimer's disease. The treatment uses electrical stimulation to target specific brain areas without surgery.
Shanghai, Shanghai MunicipalityAges 50–75 - NCT06078891Enrolling by invitationEarly Phase 1
BCG vaccine to lower Alzheimer's blood markers
This trial tests whether the BCG vaccine (a tuberculosis vaccine) can lower a blood marker linked to Alzheimer's disease. It is for people aged 70–80 who have slightly elevated p-tau181 levels but still have normal thinking and daily living skills.
JerusalemAges 70–80 - NCT06871839Recruiting
A study of lencanumab for early Alzheimer's disease
This trial tests an investigational drug called lencanumab for people with early Alzheimer's disease. The goal is to see if it can help with memory and thinking by targeting brain changes caused by Alzheimer's.
BeijingAges 50–90 - NCT04855630Recruiting
Sleep and mild exercise program for thinking and memory support
This study tests whether combining better sleep routines with mild exercise can help with memory, concentration, and thinking speed. To do that, you would wear special devices and complete quick at-home and in-person assessments and a small finger-prick blood test.
Miami, FloridaAges 45–80 - NCT06869135Recruiting
Saliva testing for brain diseases
This trial is collecting saliva samples from people with Alzheimer's, Parkinson's, or other brain diseases to find new ways to diagnose them. It may help improve early detection.
Florence, FIAges 45 years+ - NCT07435467Recruiting
Blood tests for brain health in older hospital patients
This trial looks at how blood biomarkers relate to thinking, daily function, and survival in older adults, including those with neurological issues or dementia. It aims to improve understanding and care for hospitalized seniors.
AnconaAges 65 years+ - NCT06940687Enrolling by invitation
Live Music Benefits for Early Alzheimer's Patients and Caregivers
This study tests whether listening to live music can improve brain function and well-being for people with early Alzheimer's or mild dementia, and their caregivers. You and your loved one would wear sensors to measure brain and heart activity during music sessions.
New Haven, ConnecticutAges 50–80 - NCT07758660Enrolling by invitationPhase 2
Brain scan study for Alzheimer's research
This study uses brain scans (PET) to look at changes in the brain that may be related to memory problems or Alzheimer's disease. It aims to improve understanding of the disease and may help develop better treatments.
New York, New YorkAges 50 years+ - NCT06189963RecruitingPhase 1/Phase 2
Cell therapy trial for moderate Alzheimer's disease
This trial tests a new immune cell therapy (SNK01) for people with moderate Alzheimer's disease. The goal is to see if it can slow down memory and thinking decline.
Glendale, CaliforniaAges 40–85 - NCT06889896Enrolling by invitation
Blood test for Alzheimer's brain changes
This study uses a simple blood test to quickly detect Alzheimer's-related brain changes (amyloid plaques). It may help people with memory concerns avoid a more invasive PET scan and get answers faster.
Hefei, AnhuiAges 45–85 - NCT07011745RecruitingPhase 3
Study of KarXT for Alzheimer's Agitation
This study tests a new drug combination (KarXT + KarX-EC) to see if it can safely reduce agitation in people with Alzheimer's disease. It may help if you or your loved one has bothersome agitation that affects daily life.
Chandler, ArizonaAges 55–90 - NCT07633470RecruitingPhase 4
Zunveyl for Alzheimer's disease symptoms and caregiver support
This study tests a medication called Zunveyl to see if it helps reduce behavioral and neuropsychiatric symptoms in people with mild-to-moderate Alzheimer's disease, and whether it reduces stress on family caregivers. You would need a confirmed Alzheimer's diagnosis supported by a blood test, and a dedicated caregiver who can attend visits and report on your symptoms.
Miami, FloridaAges 50 years+ - NCT04629547RecruitingPhase 2
Sleep study to help prevent Alzheimer’s disease
This trial tests whether treating sleep issues and measuring sleep can help lower the risk of Alzheimer’s disease before it starts. It focuses on older adults with no dementia signs yet.
St Louis, MissouriAges 65 years+ - NCT06274528RecruitingPhase 2
DORA and lemborexant in Alzheimer's biomarkers study
This study is testing whether a sleep medication called lemborexant can improve sleep and reduce Alzheimer's-related proteins in healthy older adults with no memory problems. It could help find new ways to delay or prevent Alzheimer's disease.
St Louis, MissouriAges 65 years+ - NCT05020106Recruiting
Tests Alzheimer’s core blood/brain markers to set diagnostic cutoffs
This study checks Alzheimer’s “core biomarkers” to find the best cut-off values for diagnosing Alzheimer’s disease and related conditions. It may help doctors more accurately tell Alzheimer’s, mild cognitive changes, and other causes of memory problems apart.
Beijing, Beijing MunicipalityAges 55–75 - NCT05059158Recruiting
Study how the brain clears amyloid in Alzheimer’s
This trial studies how the brain removes amyloid-β, a protein linked to Alzheimer’s disease. It may help researchers understand what’s happening in people with mild memory impairment or Alzheimer’s, and guide better treatments in the future.
München, BavariaAges 50–85 - NCT05573490Recruiting
Lifestyle program study for early-onset Alzheimer’s
This study tests a structured lifestyle intervention to help people with early-onset Alzheimer’s disease. It is designed for adults with confirmed Alzheimer’s-related brain changes, and may help with symptoms or day-to-day functioning.
Indianapolis, IndianaAges 40–75 - NCT05908695RecruitingPhase 4
GV-971 treatment for mild to moderate Alzheimer’s disease
This Phase 4 trial tests whether a medicine called sodium oligomannate (GV-971) is safe and effective for people with mild to moderate Alzheimer’s disease. It may help slow or improve memory and thinking symptoms while carefully tracking side effects.
Huainan, AnhuiAges 50–85 - NCT07694921Enrolling by invitation
Non-invasive brain stimulation for Alzheimer's disease
This trial tests if a safe, non-invasive electrical stimulation can help people with Alzheimer's disease. It aims to improve thinking and memory skills.
Hangzhou, ZhejiangAges 60 years+ - NCT06595511Recruiting
Combined sound, light, and games for Alzheimer's
This study tests a new approach combining special audio-visual stimulation (at 40 Hz) with cognitive games to see if it can help people with Alzheimer's disease. It also includes a group of healthy older adults for comparison.
Istanbul, BeykozAges 60–86 - NCT06657768RecruitingPhase 1
Study of LY4006895 for healthy people and those with early Alzheimer's
This trial tests a new medicine called LY4006895 in two groups: healthy volunteers and people with early symptomatic Alzheimer's disease. It aims to see how the drug works in the body and if it might help memory and thinking.
Los Alamitos, CaliforniaAges 45–85 - NCT06833645Recruiting
PET scans to spot early Alzheimer's changes
This trial uses special PET scans to see amyloid and tau proteins in the brain, which are linked to Alzheimer's. It aims to find these changes early, in people with mild memory problems or early-stage Alzheimer's.
Chengdu, SichuanAges 18 years+
Hear when a new Alzheimer's Disease Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer's disease dementia?
- Yes. Clin2 currently lists 461 recruiting alzheimer's disease dementia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer's disease dementia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer's disease dementia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.